Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matti Annala

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
BMC Bioinformatics|April 15, 2017
Segmentum: a tool for copy number analysis of cancer genomesEbrahim Afyounian, Matti Annala, Matti Nykter
Plos One|June 4, 2011
A linear model for transcription factor binding affinity prediction in protein binding microarraysMatti Annala, Kirsti Laurila, Harri Lähdesmäki, et al.
The Journal of Pathology|March 4, 2014
Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumoursBrittany C Parker, Manon Engels, Matti Annala, et al.
The Prostate|March 4, 2015
MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2Mauro Scaravilli, Kati P Porkka, Anniina Brofeldt, et al.
Communications Biology|October 2, 2018
Frequent mutation of the <i>FOXA1</i> untranslated region in prostate cancerMatti Annala, Sinja Taavitsainen, Gillian Vandekerkhove, et al.
Scientific Reports|December 23, 2017
The expression of AURKA is androgen regulated in castration-resistant prostate cancerKati Kivinummi, Alfonso Urbanucci, Katri Leinonen, et al.
JCO Precision Oncology|September 11, 2020
Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate CancerSinja Taavitsainen, Matti Annala, Elisa Ledet, et al.
Cancer Medicine|July 2, 2015
Epigenetically altered miR-193b targets cyclin D1 in prostate cancerKirsi M Kaukoniemi, Hanna E Rauhala, Mauro Scaravilli, et al.
Neuro-Oncology|April 6, 2017
Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomasKirsi J Granberg, Matti Annala, Birgitta Lehtinen, et al.
Oncogene|June 20, 2020
AR and ERG drive the expression of prostate cancer specific long noncoding RNAsAnnika Kohvakka, Mina Sattari, Anastasia Shcherban, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
BMC Bioinformatics|April 15, 2017
Segmentum: a tool for copy number analysis of cancer genomesEbrahim Afyounian, Matti Annala, Matti Nykter
Plos One|June 4, 2011
A linear model for transcription factor binding affinity prediction in protein binding microarraysMatti Annala, Kirsti Laurila, Harri Lähdesmäki, et al.
The Journal of Pathology|March 4, 2014
Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumoursBrittany C Parker, Manon Engels, Matti Annala, et al.
The Prostate|March 4, 2015
MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2Mauro Scaravilli, Kati P Porkka, Anniina Brofeldt, et al.
Communications Biology|October 2, 2018
Frequent mutation of the <i>FOXA1</i> untranslated region in prostate cancerMatti Annala, Sinja Taavitsainen, Gillian Vandekerkhove, et al.
Scientific Reports|December 23, 2017
The expression of AURKA is androgen regulated in castration-resistant prostate cancerKati Kivinummi, Alfonso Urbanucci, Katri Leinonen, et al.
JCO Precision Oncology|September 11, 2020
Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate CancerSinja Taavitsainen, Matti Annala, Elisa Ledet, et al.
Cancer Medicine|July 2, 2015
Epigenetically altered miR-193b targets cyclin D1 in prostate cancerKirsi M Kaukoniemi, Hanna E Rauhala, Mauro Scaravilli, et al.
Neuro-Oncology|April 6, 2017
Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomasKirsi J Granberg, Matti Annala, Birgitta Lehtinen, et al.
Oncogene|June 20, 2020
AR and ERG drive the expression of prostate cancer specific long noncoding RNAsAnnika Kohvakka, Mina Sattari, Anastasia Shcherban, et al.
Pageof 7